Argent BioPharma Limited (ASX:RGT)

Australia flag Australia · Delayed Price · Currency is AUD
0.0460
+0.0020 (4.55%)
At close: Mar 6, 2026
Market Cap4.00M -46.0%
Revenue (ttm)347.78K +17.6%
Net Income-8.62M
EPS-0.12
Shares Out86.94M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,818
Average Volume72,216
Open0.0450
Previous Close0.0440
Day's Range0.0450 - 0.0470
52-Week Range0.0440 - 0.3200
Beta0.13
RSI36.70
Earnings DateFeb 27, 2026

About Argent BioPharma

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company’s principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer’s. It i... [Read more]

Sector Healthcare
Founded 2014
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol RGT
Full Company Profile

Financial Performance

In fiscal year 2025, Argent BioPharma's revenue was 180,565, a decrease of -79.74% compared to the previous year's 891,083. Losses were -17.84 million, 1.79% more than in 2024.

Financial Statements